← Latest news 
Eli Lilly lifts forecasts as oral GLP 1 pill and Zepbound drive results
Business
Published on 30 April 2026
First quarter beats expectations after oral GLP-1 debut
Eli Lilly raised its annual profit and revenue outlook after a stronger-than-expected first quarter, powered by steady demand for its GLP-1 therapies. Results followed the company’s initial reporting since launching its oral GLP-1 pill, Foundayo, with continued momentum for weight-loss and diabetes brands Zepbound and Mounjaro.
- Eli Lilly beat first-quarter expectations on steady GLP-1 demand
- Company raised annual profit and revenue forecasts
- Oral GLP-1 pill Foundayo marked a key new launch cycle
- Zepbound and Mounjaro demand remained strong
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times